MedTrace Logo

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

NCT06386315 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-04-22

No results posted yet for this study

Summary

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.

Conditions

  • Indolent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
  • Refractory Indolent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Indolent Non-Hodgkin Lymphoma
  • Refractory Indolent Non-Hodgkin Lymphoma

Interventions

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Endoscopic Procedure

Undergo endoscopy

RADIATION

Involved-site Radiation Therapy (3 Fractions)

Undergo ISRT in 3 fractions

RADIATION

Involved-site Radiation Therapy (12 Fractions)

Undergo ISRT in 12 fractions

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

Principal Investigators

  • Brad S. Hoppe, MD, MPH · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2027-05-30
Completion
2027-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06386315 on ClinicalTrials.gov